Image Analysis for Automated Monitoring of Swelling and Atrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing arthritis, such as patient-reported symptoms and invasive imaging techniques, are resource-intensive, subjective, and difficult to standardize, making it challenging to accurately detect and quantify swelling, atrophy, and fibrosis in body parts.
Innovation Solution
A method involving image analysis to determine parameters indicative of swelling, atrophy, and fibrosis by retrieving images of body parts, determining contrast and shape, and classifying these features to assess the degree of swelling, atrophy, and fibrosis, which can be used to score the state of arthritis, scleroderma, or Raynaud's phenomenon, and inform pharmaceutical treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive imaging techniques (ultrasound, MRI) are used to detect swelling and atrophy, then measurement precision is improved, but device complexity and resource intensity increase
Solution Approach 1:
The patent uses digital images (copies) of body parts instead of direct invasive imaging. The system captures photographs of skin surface features and analyzes them computationally to detect swelling and atrophy, replacing complex medical imaging equipment with simple cameras and image processing algorithms.
Solution Approach 2:
The patent replaces mechanical/invasive imaging systems with an optical and computational approach. Instead of using ultrasound waves or magnetic fields, the system uses light-based photography combined with machine learning algorithms to detect physiological changes, eliminating the need for complex imaging machinery.
2Measurement precision
If clinical examination by rheumatologist is performed to assess joint swelling, then measurement precision is improved, but ease of operation deteriorates due to requirement of specialized training
Solution Approach 1:
The system enables self-assessment of swelling and atrophy through automated image analysis. Users can capture images and the system automatically processes them to provide objective measurements, eliminating the need for specialized clinical training while maintaining assessment accuracy through computational algorithms.
Solution Approach 2:
The patent introduces an intermediary computational system that bridges the gap between simple image capture and expert clinical assessment. The machine learning model acts as a mediator, translating ordinary photographs into clinically relevant measurements without requiring the operator to have rheumatologist-level expertise.
3Ease of operation
If patient-reported symptoms are used to assess disease activity, then ease of operation is improved, but measurement precision deteriorates due to subjectivity
Solution Approach 1:
The patent replaces subjective patient reporting with objective computational image analysis. Instead of relying on patient descriptions of their symptoms, the system uses algorithms to objectively measure skin surface features, eliminating bias while maintaining the simplicity of patient participation through image capture.
Data Source
AI summary
The invention relates to a method for determining a parameter indicative of the degree of swelling, atrophy and/or fibrosis of a body part of a subject and/or a method for determining a score indicative of the state of arthritis, scleroderma and/or Raynaud's phenomenon from an image of a body part. The invention further relates to a pharmaceutical composition for use in the treatment of arthritis, scleroderma and/or Raynaud's phenomenon in a subject, wherein the subject has a score indicative for an active state of arthritis, scleroderma and/or Raynaud's phenomenon determined according to method of the invention. The invention also relates to a library of a parameter indicative of the degree of swelling atrophy and/or fibrosis determined according to the method of the invention or of a score indicative of the state of arthritis, scleroderma and/or Raynaud's phenomenon determined according to the method of the invention.